BRPI0606897A2 - uso do fármaco analgésico não opiáceo flupirtina para o tratamento de bexiga superativa e doenças associadas incluindo incontinência de urgência, problemas de fluxo urinário como resultado de hiperplasia da próstata e sìndrome de intestino irritável - Google Patents

uso do fármaco analgésico não opiáceo flupirtina para o tratamento de bexiga superativa e doenças associadas incluindo incontinência de urgência, problemas de fluxo urinário como resultado de hiperplasia da próstata e sìndrome de intestino irritável

Info

Publication number
BRPI0606897A2
BRPI0606897A2 BRPI0606897-9A BRPI0606897A BRPI0606897A2 BR PI0606897 A2 BRPI0606897 A2 BR PI0606897A2 BR PI0606897 A BRPI0606897 A BR PI0606897A BR PI0606897 A2 BRPI0606897 A2 BR PI0606897A2
Authority
BR
Brazil
Prior art keywords
result
treatment
flupirtine
bowel syndrome
irritable bowel
Prior art date
Application number
BRPI0606897-9A
Other languages
English (en)
Inventor
Chris Rundfeldt
Hildegard Kuss
Regina Draheim
Katrin Bernoester
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of BRPI0606897A2 publication Critical patent/BRPI0606897A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

USO DO FáRMACO ANALGéSICO NãO OPIáCEO FLUPIRTINA PARA O TRATAMENTO DE BEXIGA SUPERATIVA E DOENçAS ASSOCIADAS INCLUINDO INCONTINêNCIA DE URGêNCIA, PROBLEMAS DE FLUXO URINáRIO COMO RESULTADO DE HIPERPLASIA DA PRóSTATA E SìNDROME DE INTESTINO IRRITáVEL. A presente invenção refere-se à prevenção, reversão e tratamento médico de disfunção do trato urinário inferior incluindo instabilidade de bexiga e outras doenças relacionadas conforme descrito abaixo incluindo problemas do fluxo urinário, urgência e incontinência como resultado de hiperpíasia da próstata (BPH) e à prevenção, reversão e tratamento médico da síndrome de intestino irritável (IBS) com especial foco na IBS tipo constipação-diarréia mista e predominante-diarréia, tanto em seres humanos como em animais.
BRPI0606897-9A 2005-01-31 2006-01-31 uso do fármaco analgésico não opiáceo flupirtina para o tratamento de bexiga superativa e doenças associadas incluindo incontinência de urgência, problemas de fluxo urinário como resultado de hiperplasia da próstata e sìndrome de intestino irritável BRPI0606897A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05001967A EP1688141A1 (en) 2005-01-31 2005-01-31 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
PCT/EP2006/000814 WO2006079559A2 (en) 2005-01-31 2006-01-31 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
BRPI0606897A2 true BRPI0606897A2 (pt) 2009-07-21

Family

ID=34933533

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606897-9A BRPI0606897A2 (pt) 2005-01-31 2006-01-31 uso do fármaco analgésico não opiáceo flupirtina para o tratamento de bexiga superativa e doenças associadas incluindo incontinência de urgência, problemas de fluxo urinário como resultado de hiperplasia da próstata e sìndrome de intestino irritável

Country Status (14)

Country Link
US (1) US7309713B2 (pt)
EP (2) EP1688141A1 (pt)
KR (1) KR20070102726A (pt)
CN (1) CN101132793A (pt)
AR (1) AR055723A1 (pt)
AU (1) AU2006208618A1 (pt)
BR (1) BRPI0606897A2 (pt)
CA (1) CA2596619A1 (pt)
IL (1) IL183557A0 (pt)
MX (1) MX2007009187A (pt)
NO (1) NO20074453L (pt)
RU (1) RU2007132725A (pt)
TW (1) TW200637548A (pt)
WO (1) WO2006079559A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) * 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
PL3409274T3 (pl) * 2008-12-22 2020-06-01 Novartis Ag Schemat dawkowania dla agonisty receptora s1p
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN109053562B (zh) * 2018-07-20 2022-05-27 四川青木制药有限公司 一种制备a晶型高堆密度的马来酸氟吡汀的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670523A1 (de) * 1966-05-12 1970-12-03 Degussa Verfahren zur Herstellung neuer substituierter Aminopyridine
DE1670255A1 (de) * 1967-08-02 1971-01-28 Basf Ag Verfahren zur Herstellung von 2-Aryl-3-amino-indazolen
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
IN172468B (pt) * 1990-07-14 1993-08-14 Asta Medica Ag
GB9220570D0 (en) 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
DE4236752A1 (de) 1992-10-30 1994-05-05 Asta Medica Ag Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit
DE4319649A1 (de) 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
AU1353901A (en) 1999-12-01 2001-06-12 Duke University Method of treating batten disease
US6412554B1 (en) * 2000-03-14 2002-07-02 Weatherford/Lamb, Inc. Wellbore circulation system
MXPA03000032A (es) 2000-06-29 2003-08-19 Neurosearch As Uso de derivados de oxindol 3-sustituidos como moduladores de los canales de potasio kcnq.
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function

Also Published As

Publication number Publication date
CA2596619A1 (en) 2006-08-03
AU2006208618A1 (en) 2006-08-03
KR20070102726A (ko) 2007-10-19
US20060173052A1 (en) 2006-08-03
NO20074453L (no) 2007-10-18
EP1688141A1 (en) 2006-08-09
WO2006079559A2 (en) 2006-08-03
WO2006079559A3 (en) 2006-11-02
US7309713B2 (en) 2007-12-18
CN101132793A (zh) 2008-02-27
AR055723A1 (es) 2007-09-05
TW200637548A (en) 2006-11-01
RU2007132725A (ru) 2009-03-10
EP1843765A2 (en) 2007-10-17
IL183557A0 (en) 2007-10-31
MX2007009187A (es) 2007-09-21

Similar Documents

Publication Publication Date Title
BRPI0606897A2 (pt) uso do fármaco analgésico não opiáceo flupirtina para o tratamento de bexiga superativa e doenças associadas incluindo incontinência de urgência, problemas de fluxo urinário como resultado de hiperplasia da próstata e sìndrome de intestino irritável
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
GB2467670A (en) Chemical entities and therapeutic uses thereof
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BRPI0511477A (pt) compostos e composições como moduladores de ppar
ECSP088762A (es) Tratamiento del dolor
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
MX2009005597A (es) Miembros de enlace para interleucina 6.
NO20084341L (no) Anvendelse av DPP-IV inhibitorer
BRPI0811436A2 (pt) Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto.
EA201390497A1 (ru) Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
BRPI0720500A8 (pt) Preparação líquida transdérmica
BRPI0813882A2 (pt) Composições e tratamento de insuficiência cardíaca em animais mamíferos não humanos.
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
DK1829548T3 (da) Anvendelse af Pelargoniumekstrakter i kombination med Plantago til fremstilling af et medikament til behandling af halsbetændelse
AR057876A1 (es) Tratamiento de pacientes con enfermedad renal cronica (erc) utilizando compuestos de la invencion
NO20076463L (no) Synergetiske kombinasjoner
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
MX2010009640A (es) Uso de conjugados de interleucina-1 en el tratamiento de diabetes.
MY184048A (en) Arylsulfonamide ccr3 antagonists

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]